A new electrocardiogram marker to identify patients at low risk for ventricular tachyarrhythmias: sum magnitude of the absolute QRST integral

doi:10.1016/j.jelectrocard.2010.08.012

Journal of Electrocardiology

Volume 44, Issue 2, March–April 2011, Pages 208-216

https://doi.org/10.1016/j.jelectrocard.2010.08.012 Get rights and content

Abstract

Objective

We proposed and tested a novel electrocardiogram marker of risk of ventricular arrhythmias (VAs).

Methods

Digital orthogonal electrocardiograms were recorded at rest before implantable cardioverter-defibrillator (ICD) implantation in 508 participants of a primary prevention ICDs prospective cohort study (mean ± SD age, 60 ± 12 years; 377 male [74%]). The sum magnitude of the absolute QRST integral in 3 orthogonal leads (SAI QRST) was calculated. A derivation cohort of 128 patients was used to define a cutoff; a validation cohort (n = 380) was used to test a predictive value.

Results

During a mean follow-up of 18 months, 58 patients received appropriate ICD therapies. The SAI QRST was lower in patients with VA (105.2 ± 60.1 vs 138.4 ± 85.7 mV ⁎ ms, P = .002). In the Cox proportional hazards analysis, patients with SAI QRST not exceeding 145 mV ⁎ ms had about 4-fold higher risk of VA (hazard ratio, 3.6; 95% confidence interval, 1.96-6.71; P < .0001) and a 6-fold higher risk of monomorphic ventricular tachycardia (hazard ratio, 6.58; 95% confidence interval, 1.46-29.69; P = .014), whereas prediction of polymorphic ventricular tachycardia or ventricular fibrillation did not reach statistical significance.

Conclusion

High SAI QRST is associated with low risk of sustained VA in patients with structural heart disease.

Section snippets

Methods

The study protocol was approved by the Johns Hopkins University institutional review board, and all patients gave written informed consent before entering the study.

Patient population

Clinical characteristics of the derivation and validation cohort patients are outlined in Table 1. There were no statistically significant differences between baseline characteristics of the 2 cohorts. Neither did the rate of VT/VF events differ significantly (15 patients [11.7%] in derivation cohort vs 43 patients [11.3%] in validation cohort experienced VT/VF; P = .901). A few differences in patient management were observed: derivation cohort patients were more frequently on β-blockers and

Discussion

In this study, we present a new marker of low risk of ventricular tachyarrhythmias and show that SAI QRST greater than 145 mV ⁎ ms is associated with a low risk of arrhythmia in structural heart disease patients with implanted ICD for primary prevention of SCD.

Substantial evidence supports the idea that patients with structural heart disease have some degree of risk of VA during their lifetime. The strategy of identifying patients at low, rather than high, risk of VA maximizes the benefit of

Limitations

Appropriate ICD therapy as a surrogate for sudden death may overestimate the frequency of SCD.³⁴ This is a well-recognized and unavoidable limitation in the ICD era, as it would be unethical to withhold ICD therapy to study the actual death rate. The use of ICD events as the end point for validation of a risk stratifier is frequently viewed as a weak surrogate for actual mortality. However, as soon as the VT/VF risk stratification guides the decision about whether to implant an ICD, then a risk

References (39)

GoldenbergI. et al.
Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction
J Am Coll Cardiol
(2008)
BuxtonA.E. et al.
Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study
J Am Coll Cardiol
(2007)
OkinP.M. et al.
Electrocardiographic diagnosis of left ventricular hypertrophy by the time-voltage integral of the QRS complex
J Am Coll Cardiol
(1994)
OkinP.M. et al.
Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products
J Am Coll Cardiol
(1995)
WilsonF.N. et al.
The determination and the significance of the areas of the ventricular deflections of the electrocardiogram
Am Heart J
(1934)
GoldbergerJ.J.
Evidence-based analysis of risk factors for sudden cardiac death
Heart Rhythm
(2009)
BurgerH.C.
A theoretical elucidation of the notion ventricular gradient
Am Heart J
(1957)
BurgessM.J. et al.
Cancellation of electrocardiographic effects during ventricular recovery
J Electrocardiol
(1969)
BuxtonA.E. et al.
QRS duration does not predict occurrence of ventricular tachyarrhythmias in patients with implanted cardioverter-defibrillators
J Am Coll Cardiol
(2005)
DharR. et al.
Association of prolonged QRS duration with ventricular tachyarrhythmias and sudden cardiac death in the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II)
Heart Rhythm
(2008)

OkinP.M.

Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients

J Electrocardiol

(2009)

Lloyd-JonesD. et al.

Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

Circulation

(2009)

A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators

N Engl J Med

(1997)

MossA.J. et al.

Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction

N Engl J Med

(2002)

BardyG.H. et al.

Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure

N Engl J Med

(2005)

PalmeriS.T. et al.

A QRS scoring system for assessing left ventricular function after myocardial infarction

N Engl J Med

(1982)

SelvesterR.H. et al.

The Selvester QRS scoring system for estimating myocardial infarct size. The development and application of the system

Arch Intern Med

(1985)

WagnerG.S. et al.

Evaluation of a QRS scoring system for estimating myocardial infarct size. I. Specificity and observer agreement

Circulation

(1982)

KleberA.G. et al.

Basic mechanisms of cardiac impulse propagation and associated arrhythmias

Physiol Rev

(2004)

Cited by (38)

Exploring vectorcardiography: An extensive vectocardiogram analysis across age, sex, BMI, and cardiac conditions
2024, Journal of Electrocardiology
The vectocardiogram (VCG) offers a three-dimensional view of the heart's electrical activity, yet many VCG parameters remain unexplored in diverse clinical contexts.
This study aims to explore the relationships between various VCG parameters and specific patient characteristics.
ECG signals from adults were transformed into VCGs utilizing the Kors matrix, yielding 315 parameters per patient from the P, QRS and T loops. Univariable analysis, circular statistics, and stepwise logistic regression were employed to examine the relationships between VCG parameters and factors such as age, sex, BMI, hypertension, echocardiographic ischemic heart disease (Echo-IHD), and left ventricular hypertrophy (Echo-LVH).
We included 664 adults and considered an alpha value of 0.05 and a power of 90%. The study revealed significant associations, such as age with P loop roundness index (RI) (OR = 3.825, 95% confidence interval [95%CI] = 2.079–7.04), male sex with QRS loop RI (OR = 6.08, 95%CI = 1.835–20.153), abnormal BMI with the T loop's RI (OR = 0.544, 95%CI = 0.325–0.909), hypertension with the T loop planarity index (PI) (OR = 8.01, 95%CI = 2.134–30.117), Echo-IHD with QRS loop curvature at the 4/10th segment (OR = 7.58, 95%CI = 1.954–29.458), and Echo-LVH with the T loop lag-1/10 dihedral angle (OR = 10.3, 95%CI = 1.822–58.101). In the study, several additional VCG parameters demonstrated statistically significant, albeit smaller, associations with patient demographics and cardiovascular conditions.
The findings enhance our understanding of the intricate relationships between VCG parameters and patient characteristics, emphasizing the potential role of VCG analysis in assessing cardiovascular diseases. These insights may guide future research and clinical applications in cardiology.
BRAVEHEART: Open-source software for automated electrocardiographic and vectorcardiographic analysis
2023, Computer Methods and Programs in Biomedicine
Electrocardiographic (ECG) and vectorcardiographic (VCG) analyses are used to diagnose current cardiovascular disease and for risk stratification for future adverse cardiovascular events. With increasing use of digital ECGs, research into novel ECG/VCG parameters has increased, but widespread computer-based ECG/VCG analysis is limited because there are no currently available, open-source, and easily customizable software packages designed for automated and reproducible analysis.
We present BRAVEHEART, an open-source, modular, customizable, and easy to use software package implemented in the MATLAB programming language, for scientific analysis of standard 12-lead ECGs acquired in a digital format. BRAVEHEART accepts a wide variety of digital ECG formats and provides complete and automatic ECG/VCG processing with signal denoising to remove high- and low-frequency artifact, non-dominant beat identification and removal, accurate fiducial point annotation, VCG construction, median beat construction, customizable measurements on median beats, and output of measurements and results in numeric and graphical formats.
The BRAVEHEART software package provides easily customizable scientific analysis of ECGs and VCGs. We hope that making BRAVEHART available will allow other researchers to further the field of ECG/VCG analysis without having to spend significant time and resources developing their own ECG/VCG analysis software and will improve the reproducibility of future studies. Source code, compiled executables, and a detailed user guide can be found at http://github.com/BIVectors/BRAVEHEART. The source code is distributed under the GNU General Public License version 3.
Spatial Ventricular Gradient: A Measure of Global Electrical Heterogeneity
2023, JACC: Advances
Association between T wave morphology parameters and abnormal cardiac SPECT imaging
2022, Journal of Electrocardiology
T-wave morphology dispersion (TMD) described the electrocardiographic T-wave heterogeneity during a single cardiac cycle. Total cosine R-to-T (TCRT) is the average of the cosines of the angles between the QRS and T vectors on the ECG. We examine the predictive value of TMD and TCRT calculation to assess abnormal myocardial perfusion.
Retrospective single center cohort study including all patients referred for evaluation of ischemia by myocardial SPECT scanning with no known history of ischemic heart disease, from 1 January 2019 to 31 December 2019. Study endpoint was the correlation between the calculated TMD and TCRT values and detection of myocardial injury or ischemia by myocardial SPECT.
Among 606 patients, calculated TCRT was 0.401 ± 0.53 for the normal group and 0.283 ± 0.62 for the abnormal group (p = 0.007). Measured TMD was 22.9 ± 16.6 degrees (p < 0.001) in the normal group, compared to 31.5 ± 22.8 degrees (p < 0.001) for the abnormal group.
The results demonstrate a correlation between the decreased TCRT values and increase TMD and myocardial ischemia seen in SPECT results. The TCRT and TMD can be used as simple and non-invasive markers to predict abnormal SPECT results and ischemic heart disease in patients with no known cardiac history.
Reproducibility of global electrical heterogeneity measurements on 12-lead ECG: The Multi-Ethnic Study of Atherosclerosis
2021, Journal of Electrocardiology
Citation Excerpt :
Vectorcardiographic (VCG) global electrical heterogeneity (GEH) metrics showed their clinical usefulness in heart failure patients with implanted primary prevention cardioverter-defibrillators [1–4] and in the general population [5–10].
Vectorcardiographic (VCG) global electrical heterogeneity (GEH) metrics showed clinical usefulness. We aimed to assess the reproducibility of GEH metrics.
GEH was measured on two 10-s 12‑lead ECGs recorded on the same day in 4316 participants of the Multi-Ethnic Study of Atherosclerosis (age 69.4 ± 9.4 y; 2317(54%) female, 1728 (40%) white, 1138(26%) African-American, 519(12%) Asian-American, 931(22%) Hispanic-American). GEH was measured on a median beat, comprised of the normal sinus (N), atrial fibrillation/flutter (S), and ventricular-paced (VP) beats. Spatial ventricular gradient's (SVG's) scalar was measured as sum absolute QRST integral (SAIQRST) and vector magnitude QT integral (VMQTi).
Two N ECGs with heart rate (HR) bias of −0.64 (95% limits of agreement [LOA] -5.68 to 5.21) showed spatial area QRS-T angle (aQRST) bias of −0.12 (95%LOA −14.8 to 14.5). Two S ECGs with HR bias of 0.20 (95%LOA −15.8 to 16.2) showed aQRST bias of 1.37 (95%LOA −33.2 to 35.9). Two VP ECGs with HR bias of 0.25 (95%LOA −3.0 to 3.5) showed aQRST bias of −1.03 (95%LOA −11.9 to 9.9). After excluding premature atrial or ventricular beat and two additional beats (before and after extrasystole), the number of cardiac beats included in a median beat did not affect the GEH reproducibility. Mean-centered log-transformed values of SAIQRST and VMQTi demonstrated perfect agreement (Bias 0; 95%LOA −0.092 to 0.092).
GEH measurements on N, S, and VP median beats are reproducible. SVG's scalar can be measured as either SAIQRST or VMQTi.
Satisfactory reproducibility of GEH metrics supports their implementation.
Competing risks in patients with primary prevention implantable cardioverter-defibrillators: Global Electrical Heterogeneity and Clinical Outcomes study
2021, Heart Rhythm
Citation Excerpt :
We constructed spatial peak and area QRS and T vectors as well as their vector sum (SVG) and measured their magnitude, direction (azimuth [orientation in the XZ plane] and elevation [orientation in the XY plane]), and spatial QRS-T angles (Figure 1).7,11,12 Scalar approximations of the SVG were measured via the sum absolute QRST integral (SAIQRST)13–15 and the QT integral on vector magnitude (VMQTi).11 Quality control of automated ECG analysis was performed to verify appropriate beat identification and fiducial point annotation (K.T.H.).
Global electrical heterogeneity (GEH) is associated with sudden cardiac death in the general population. Its utility in patients with systolic heart failure who are candidates for primary prevention (PP) implantable cardioverter-defibrillators (ICDs) is unclear.
The purpose of this study was to investigate whether GEH is associated with sustained ventricular tachycardia/ventricular fibrillation leading to appropriate ICD therapies in patients with heart failure and PP ICDs.
We conducted a multicenter retrospective cohort study. GEH was measured by spatial ventricular gradient (SVG) direction (azimuth and elevation) and magnitude, QRS-T angle, and sum absolute QRST integral on preimplant 12-lead electrocardiograms. Survival analysis using cause-specific hazard functions compared the strength of associations with 2 competing outcomes: sustained ventricular tachycardia/ventricular fibrillation leading to appropriate ICD therapies and all-cause death without appropriate ICD therapies.
We analyzed 2668 patients (mean age 63 ± 12 years; 624 (23%) female; 78% white; 43% nonischemic cardiomyopathy; left ventricular ejection fraction 28% ± 11% from 6 academic medical centers). After adjustment for demographic, clinical, device, and traditional electrocardiographic characteristics, SVG elevation (hazard ratio [HR] per 1SD 1.14; 95% confidence interval [CI] 1.04–1.25; P = .004), SVG azimuth (HR per 1SD 1.12; 95% CI 1.01–1.24; P = .039), SVG magnitude (HR per 1SD 0.75; 95% CI 0.66–0.85; P < .0001), and QRS-T angle (HR per 1SD 1.21; 95% CI 1.08–1.36; P = .001) were associated with appropriate ICD therapies. Sum absolute QRST integral had different associations in infarct-related cardiomyopathy (HR 1.29; 95% CI 1.04–1.60) and nonischemic cardiomyopathy (HR 0.78; 95% CI 0.62–0.96) (P_interaction = .022).
In patients with PP ICDs, GEH is independently associated with appropriate ICD therapies. The SVG vector points in distinctly different directions in patients with 2 competing outcomes.

View all citing articles on Scopus

^☆: Financial support and conflicts of interest: National Institutes of Health HL R01 091062 (Gordon Tomaselli) and American Heart Association 10CRP2600257 (Larisa Tereshchenko); Donald W Reynolds Foundation. Other coauthors have nothing to disclose.

^☆☆: Registration identification no. NCT00733590.

View full text

A new electrocardiogram marker to identify patients at low risk for ventricular tachyarrhythmias: sum magnitude of the absolute QRST integral☆,☆☆

Abstract

Objective

Methods

Results

Conclusion

Section snippets

Methods

Patient population

Discussion

Limitations

J Am Coll Cardiol

J Am Coll Cardiol

J Am Coll Cardiol

J Am Coll Cardiol

Am Heart J

Heart Rhythm

Am Heart J

J Electrocardiol

J Am Coll Cardiol

Heart Rhythm

J Electrocardiol

Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

Circulation

A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators

N Engl J Med

Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction

N Engl J Med

Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure

N Engl J Med

A QRS scoring system for assessing left ventricular function after myocardial infarction

N Engl J Med

The Selvester QRS scoring system for estimating myocardial infarct size. The development and application of the system

Arch Intern Med

Evaluation of a QRS scoring system for estimating myocardial infarct size. I. Specificity and observer agreement

Circulation

Basic mechanisms of cardiac impulse propagation and associated arrhythmias

Physiol Rev